Pelthos Therapeutics Inc.
PTHS- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001919246
In the last 90 days, Pelthos Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $37.4M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Pelthos Therapeutics Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 17 | 24 | +7 |
| Shares | 912.3K | 1.32M | +410.9K (+45.0%) |
| Value | $19.2M | $37.4M | +$18.2M (+95.1%) |
New holders (10)
Institutions that held Pelthos Therapeutics Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| AIGH Capital Management LLC | 329,098 | $9.30M | 0.84% |
| Wexford Capital LP | 22,364 | $632.0K | 0.09% |
| Citadel Advisors LLC | 15,046 | $425.2K | 0.00% |
| 1492 Capital Management LLC | 10,380 | $293.3K | 0.09% |
| State Street Corp | 9,800 | $276.9K | 0.00% |
| BlackRock, Inc. | 5,324 | $150.5K | 0.00% |
| China Universal Asset Management Co., Ltd. | 2,160 | $61.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 205 | $5.79K | 0.00% |
| Barclays PLC | 20 | $565 | 0.00% |
| Royal Bank of Canada | 6 | $0 | 0.00% |
Sold out (3)
Institutions that held Pelthos Therapeutics Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Steward Partners Investment Advisory, LLC | 1,910 | $40.1K |
| Aspect Partners, LLC | 16 | $336 |
| Citigroup Inc | 1 | $21 |